Morbidity and mortality attributable to Rothia bacteremia in neutropenic and nonneutropenic patients

Diagn Microbiol Infect Dis. 2016 May;85(1):116-20. doi: 10.1016/j.diagmicrobio.2016.01.005. Epub 2016 Jan 12.

Abstract

Rothia spp. are increasingly being recognized as emerging opportunistic pathogens associated with serious infections in immune-compromised hosts. Risk factors include neutropenia, hematologic malignancies, prosthetic devices, and intravascular catheters. We describe 29 patients at our institute from 2006 to 2014 with positive blood cultures for Rothia spp. Neutropenia was observed in 21/29 (72%) patients at the time of bacteremia, and 16/29 (61%) had leukemia. Neutropenic patients were less likely than nonneutropenic patients to have polymicrobial infection (24% versus 63%; P= 0.083) and were also more likely to have multiple positive blood cultures (76% versus 0%; P= 0.0003), indicating true infection. Sources of bacteremia included intravascular catheters, mucositis, and presumed gut translocation. A significant association was seen with steroid use (81% versus 13%; P= 0.0014) and fluoroquinolone use (86% versus 13%; P≤ 0.0001) preceding bacteremia in neutropenic patients. There was no difference between the 2 groups for admission to intensive care unit or mortality. One death was reported possibly due to Rothia infection.

Keywords: Bacteremia; Neutropenia; Rothia mucilaginosa.

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / drug therapy
  • Bacteremia / epidemiology*
  • Bacteremia / etiology*
  • Comorbidity
  • Female
  • Gram-Positive Bacterial Infections / epidemiology*
  • Gram-Positive Bacterial Infections / etiology*
  • Hematologic Neoplasms / complications
  • Hematologic Neoplasms / therapy
  • Humans
  • Incidence
  • Male
  • Micrococcaceae*
  • Middle Aged
  • Morbidity
  • Mortality
  • Neutropenia / complications*
  • Retrospective Studies
  • Stem Cell Transplantation / adverse effects

Substances

  • Anti-Bacterial Agents